



Accelerate your Renal Cell Carcinoma (RCC) Pharmacokinetic studies with efficient patient recruitments

Veeda Clinical Research Pvt. Ltd. is India's most experienced early phase clinical development CRO with a global outreach providing **ethical Clinical Research Solutions**. With a competent team of **250 experienced scientists** and **a stern focus on providing quality solutions**, we are the ideal partner to accelerate your clinical trial programmes.

RCC Trials Challenges

1

Identifying Competent Investigator Sites: Identifying sufficient number of sites with experience, infrastructure and quality systems is the key deciding factor for the overall deliverables.

2

Patient Recruitments: Being a rare indication in developing countries, timely recruitment is a challenge.

3

Patient Retention: The advanced state of the disease, co-morbidities and duration of trial pose challenges in patient retention.

We at Veeda, have already succeeded in recruiting **58 RCC patients within competitive timelines of 3.5 months.**

We are now offering our expertise and learning to help you overcome the challenges in RCC PK studies.

Generic molecules for RCC patients

- Everolimus
- Sunitinib
- Pazopanib

Our capabilities

- Dynamic database of **pre-screened experienced RCC Investigators sites** in India and Southeast Asia.
- **Excellent regulatory liaison** to accelerate the approval process.
- **Scientific Project Management Team** sensitive to project needs.
- **100% data review** by Quality Assurance.

Our Achievements

Fast recruitment rate even for rare indications like **SCLC, RCC**

Road Map for **more than 25 molecules for Patient based Pharmacokinetic Studies** and **more than 15 molecules for Clinical End Point Studies**

[CLICK HERE TO KNOW MORE](#)

Proven regulatory track record with **8 USFDA, 4 European, 4 WHO & 7 ANVISA** audits

State of the art Bio-analytical Unit with more than **340 validated assays** in its library of compounds, **35 NCE methods** and **20 more under development.**